Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Among authors: stuve o. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Are statins a treatment option for multiple sclerosis?
Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Neuhaus O, et al. Among authors: stuve o. Lancet Neurol. 2004 Jun;3(6):369-71. doi: 10.1016/S1474-4422(04)00770-7. Lancet Neurol. 2004. PMID: 15157852 Review.
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.
Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Frohman EM, et al. Among authors: stuve o. Arch Neurol. 2005 Sep;62(9):1345-56. doi: 10.1001/archneur.62.9.1345. Arch Neurol. 2005. PMID: 16157741 Review.
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: stuve o. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
Acute disseminated encephalomyelitis: an update.
Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, Kieseier BC, Stüve O. Menge T, et al. Among authors: stuve o. Arch Neurol. 2005 Nov;62(11):1673-80. doi: 10.1001/archneur.62.11.1673. Arch Neurol. 2005. PMID: 16286539 Review.
Optical coherence tomography in multiple sclerosis.
Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, Trip A, Frohman T, Balcer L. Frohman E, et al. Among authors: stuve o. Lancet Neurol. 2006 Oct;5(10):853-63. doi: 10.1016/S1474-4422(06)70573-7. Lancet Neurol. 2006. PMID: 16987732 Review.
Multiple sclerosis therapy: an update on recently finished trials.
Kleinschnitz C, Meuth SG, Stüve O, Kieseier B, Wiendl H. Kleinschnitz C, et al. Among authors: stuve o. J Neurol. 2007 Nov;254(11):1473-90. doi: 10.1007/s00415-007-0684-7. Epub 2007 Nov 15. J Neurol. 2007. PMID: 18004638 Review.
Pharmacological treatment of early multiple sclerosis.
Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Stüve O, et al. Drugs. 2008;68(1):73-83. doi: 10.2165/00003495-200868010-00005. Drugs. 2008. PMID: 18081373 Review.
315 results